Drugs / Antiwei Granules
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06697886 | Nov 2023 → Jun 2025 overdue | common cold | Tasly Pharmaceutical Group Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Antiwei Granules | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06697886 ↗ |
| Route | Oral | “Oral administration” NCT06697886 ↗ |